CONNECT WITH PURPOSE

Together we can make an impact on patients’ lives. Let’s all connect for one purpose—giving our patients new hope.

Connecting

The TECENTRIQ experience across indications

Roche is investing in bringing personalized immunotherapy to people with cancer. TECENTRIQ is approved as monotherapy or in combination with other medicines in several cancer types. Click the links below to learn more.

Learn more about TECENTRIQ and NSCLC

Learn more about TECENTRIQ and
SCLC

Learn more about TECENTRIQ and Hepatocellular carcinoma

Learn more about TECENTRIQ and Urothelial carcinoma

Learn more about TECENTRIQ and Breast cancer

Connecting

YOU WITH YOUR PATIENTS

At Roche, we understand and empathize with the demands you face when identifying and individualizing treatment options for your patients with difficult-to-treat cancer.

CONNECTING YOU WITH YOUR PATIENTS

At Roche, we believe in a shared purpose in improving the care and treatment of patients living with difficult to treat cancers. We understand and empathise with the demands you face managing the needs of these patients.

Roche is committed to exploring new treatment options to individualise treatment and meet patients’ needs. TECENTRIQ has proven efficacy as monotherapy as well as in combination with other medicines and we are committed to exploring new combinations to improve patient outcomes (ref. SmPC).

TECENTRIQ is an anti PD-L1 cancer immunotherapy that specifically targets PD-L1 on tumour and tumour-infiltrating immune cells across a broad range of solid tumours. TECENTRIQ offers a pioneering, targeted treatment with proven efficacy and an acceptable tolerability profile (ref. SmPC). 

Please see the specific indications for more information.

Connecting

TECENTRIQ AND COMBINATIONS

TECENTRIQ has proven efficacy as monotherapy as well as in combination with other medicines. Roche is committed to exploring new TECENTRIQ combinations for better patient outcomes.

CONNECTING TECENTRIQ AND COMBINATIONS

TECENTRIQ has proven efficacy as monotherapy as well as in combination with other medicines and we are committed to explore new combinations for better patient outcomes (ref. SmPC).

In many difficult-to-treat tumour types with a high unmet need, including metastatic urothelial carcinoma, triple negative breast cancer and lung cancer (non-small cell lung cancer and small cell lung cancer), TECENTRIQ has shown significant improvements in progression-free and/or overall survival (ref. SmPC). Importantly, treatment can be tailored (i.e., in combination with the standard of care, or different dosing schedules) according to the type of cancer and the patient’s individual needs (ref. SmPC).
Read SmPC for more details
The multiple indications of TECENTRIQ (ref. SmPC) provide a wealth of data to inform treatment decision-making and deliver valuable reassurance when considering the needs of your patients with cancer. Please see the specific indications for more information.

Connecting

PATIENTS TO THEIR LOVED ONES

Multiple clinical studies of TECENTRIQ demonstrated its potential to improve and prolong the lives of your patients.

CONNECTING PATIENTS TO THEIR LOVED ONES

TECENTRIQ treatment offers the potential to improve treatment outcomes and maintain patient quality of life in your difficult to treat cancer patients, so they can hopefully spend more time with their loved ones.

TECENTRIQ is approved in metastatic urothelial carcinoma, non-small cell lung cancer, extensive-stage small cell lung cancer and triple negative breast cancer (ref. SmPC).

TECENTRIQ's position in lung cancer

Connect to more information on your local product website

ASIA

Select a Country

Hong Kong

India

Israel

Kuwait

Qatar

Singapore

South Korea

Taiwan

Thailand

Hong Kong

medinfo.roche.com

India

medinfo.roche.com

Israel

medinfo.roche.com

Kuwait

medinfo.roche.com

Qatar

medinfo.roche.com

Singapore

medinfo.roche.com

South Korea

medinfo.roche.com

Taiwan

medinfo.roche.com

Thailand

medinfo.roche.com

By choosing your country, you will be redirected to a Healthcare Professional Portal. Please be aware that it may require registration or log-in to access certain areas.

AFRICA

Select a Country

No country found.

By choosing your country, you will be redirected to a Healthcare Professional Portal. Please be aware that it may require registration or log-in to access certain areas.

OCEANIA

Select a Country

Australia

New Zeland

Australia

www.rocheinteract.com.au
medinfo.roche.com

New Zealand

medinfo.roche.com

By choosing your country, you will be redirected to a Healthcare Professional Portal. Please be aware that it may require registration or log-in to access certain areas.

Global select

Select a Country

Argentina

Australia

Brazil

Canada

Chile

Croatia

Czech Republic

Denmark

El Salvador

France